Ligand Pharmaceuticals | LGND - Прибыль до налогообложения





Прибыль до налогообложения Изменить Дата
Agenus USD -10.61M 263.52M 2025-12
Amgen USD 1.51B 2.41B 2025-12
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD 28.27M 7.85M 2025-12
Baxter International USD -756M 877M 2025-12
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Enviri Corporation USD 233.18M 21.88M 2026-03
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Glaxosmithkline GBP 2.46B 569M 2025-09
Heron Therapeutics USD -2.95M 14.54M 2025-12
Insmed USD -162.1M 164.84M 2026-03
Intrexon USD -60.48M 27.09M 2024-06
Ionis Pharmaceuticals USD -93M 135M 2026-03
Karyopharm Therapeutics USD -39.9M 9.01M 2025-12
Ligand Pharmaceuticals USD 56.78M 84.36M 2025-12
MacroGenics USD -14.93M 31.75M 2025-12
Merck USD 3.42B 3.32B 2025-12
Pacira USD 571K 8.95M 2025-12
Pfizer USD 5.18B 6.82B 2026-03
Rigel Pharmaceuticals USD -1.03M 7.22M 2024-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Veracyte USD 29.97M 10.66M 2026-03